Drug sensitivity of human immunodeficiency virus type 1 isolates after ribavirin therapy.
The antiviral agent ribavirin is effective against several virally induced diseases, and there is evidence that it might prove useful against human immunodeficiency virus type 1 (HIV-1) infection. Thus, there is interest in studying the resistance level of HIV-1 isolates to ribavirin following drug therapy. Low-passage clinical strains of HIV-1 were isolated from 3 patients undergoing treatment with ribavirin for 5-9 months. No significant changes in drug sensitivity were seen for sequential virus samples obtained before, during, and after antiviral therapy. These observations suggest that the appearance of a resistant phenotype is not induced by treatment with ribavirin in HIV-1-infected persons.
Bernier
R
R
Centre de Recherche en Infectiologie, Département de Microbiologie, Faculté de Médecine, Université Laval, Ste-Foy, Montreal, Canada.
Tremblay
M
M
Tsoukas
C
C
Bergeron
M G
MG
D000328:Adult; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004311:Double-Blind Method; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D012254:Ribavirin / Q000494:pharmacology* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D012254:Ribavirin